Drugs / DUOFAG®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06319235 | Oct 2023 → Dec 2025 | Pseudomonas aeruginosa infectious disease, staphylococcus aureus infection | MB PHARMA s.r.o. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DUOFAG | “DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.” NCT06319235 ↗ |
| Modality | Other / unclassified | “DUOFAG® is a phage cocktail” NCT06319235 ↗ |
| Route | Topical | “DUOFAG® will be sprayed on the surgical wound.” NCT06319235 ↗ |